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Objectives, This study characterized mortality in a group of 
Mexican children (n = 18, mean [*SD] age 9.9 2 3 years) with 
primary pulmonary hypertension and investigated the factors 
zsssociated with their survival. 
Background. Primary pulmonary hypertension is a progressive, 
fatal dise:lse of unknown cause. Establishing the diagnosis earlier 
in life may influence prognosis. 
Methods. A dynamic cohort of children with primary pulmo- 
nary hypertension were enrolled between December 1977 and May 
1991 and followed up through September 1992. Measurements 
included hemodynamic and pulmonary function variables in 
addition to demographic data, medical history and response to 
vasodilator treatment. We also compared the survival estimates of 
these c&!dren with those of our adult patients with primary 
pulmonary hypertension (n = 42, mean age 27.9 f 8.5 years). 
Results. Baseline mean (*SD) pulmonary artery pressure was 
similar in children and aduits (66 -C 15 vs. 65 f 18 mm Hg, p = 
NS), but a higher cardiac index resulted in a lower mean 
Primary pulmonary hypertension is an uncommon disease that 
affects predominantly young people (l-3). Recent studies 
(4-6) on the natural history of this disease have shown it to 
have a highly variable course. Although patients with a typical 
mean survival period of 2 to 3 years from the time of diagnosis 
have been described (2,3,7,8), patients with a survival period 
>5 to 10 years have also been well documented (3,5,6,8-IO); 
and although uncommon, even spontaneous regression of the 
disease has been described (11,12). In our experience (13) and 
that of the US. National Institutes of Health multicenter study 
on primary pulmonary hypertension (6), at least 30% of 
patients with primary pulmnnary hypertension have survived 
X years. In these two studies, survival was largely related to 
the hemodynamic profile of the patient at the time of diagno- 
sis, a finding also suggested previously by other investigators 
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pulmonary vascular resistance ig,dex in children (18 2 7 vs. 26 * 
12 U/m’, p < 0.01). The proportion of patients who had a positive 
hemodynamic response to vasoailator treatment was higher in 
children than in adults (41% vs. 25%). Estimated median survival 
in children was 4.12 years (95% confidence interva! [!:I] 0.75 to 
8.66) and 3.12 years in adults (95% CI 0.5 to 13.25, chi-square 
log-rank 0.81, p = NS). Elevated right atrial pressure (rate ratio 
10.2) and decreased stroke volume index (rate ratio 32.9) were the 
only significant predictors of mortality (Cox proportional hazards 
model). 
Conclusions. Children with primary pulmonary hypertension 
have a poor survival expectancy, which does not appear to differ 
from that in adults with primary pulmonary hypertension. 
Mortality in childhood primary pulmonary hypertension is also 
associated with variables that assess right ventricular dysfunc- 
tion. 
(J Am Coil Cardiol1995;25:466-74) 
(3,8,14-16). Accordingly, it would appear that there is a subset 
ul patients with primary pulmonary hypertension who have a 
better hemodynamic profile at diagnosis, and as a conse- 
quence, a better long-term prognosis. 
An important and still unsolved question is whether the 
better hemodynamic profile and long-term prognosis shown by 
some patients with primary pulmonary hypertension reflects a 
different stage, a Sower progression rate or even a different 
form of the disease. To address this question, we analyzed Ihe 
natural history and survival of children with primary pulmonary 
hypertension and compared them with that in our adult patients 
with primary pulmonary hypertension. We hypothesized that 
establishing the diagnosis of primary pulmonary hypertension at 
an earlier stage of life would make a difference in prognosis. 
At our institution, the availability of vasodilator drug testing 
since 1977 has led to the referral of s large number of patients 
with primary pulmonary hypertension for possible medical 
treatment. In the present report we evaluate part of our 
experience derived from a prospective study of children with 
primar): pulmonary hypertension. We describe their clinical 
and hemodynamic characteristics at entry and analyze the 
variables associated with their mortality. 
073%1097/!%$9.511 
073s10!37(94)0(3391-3 
JACC Vol. 2.5. No. 7 
February 1995:466-74 
SANDOVAL ET AL. 467 
PRIMARY PULMONARY HYPERTENSION IN CHILDREN 
Mzthods 
Patients. The qtudy series included 18 children ~16 years 
of age (range 4 to 15) in whom primary pulmonary hyperten- 
sion was diagnosed at our institution between December 1977 
and May 1991 and who were followed up through September 
1992. These patients are among the 61 who comprise the 
institutional registry for primary pulmonary hypertension (13). 
The diagnostic as well as therapeutic approach in these 
patients has followed strict clinical and hemodynamic criteria 
that have remained basically unchanged over the years. As in 
other studies (3,4,8), every patient has had a thorough workup, 
including clinical history and physical examination, laboratory 
tests, chest roentgenography, electrocardiography, pulmonary 
function tests when feasible, echocardiography, radionuclide 
perfusion lung scan and cardiac catheterization. All proce- 
dures were approved by our local commiiiee for clinical 
investigation. They were explained to the parents of the 
children, and their written consent was obtained. 
Criteria used to establish the diagnosis of primary pulmo- 
nary hypertension included the presence of elevated mean 
pulmonary artery pressure >22 mm Hg at rest, a normal 
pulmonary capillary wedge pressure when measurable and the 
absence of other diseases known to cause or :a be associated 
with secondary pulmonary hypertension (3,4,8). Particular care 
was taken to exclude patients with evidence of congenital heart 
disease or acquired valvular or myocardial disease; obstructive 
or restrictive lung disease, or both; parasitic disease involving 
the lungs; pulmonary thromboembolic and clearly defined 
collagen vascu!ar disease; and the antiphospholipid syndrome. 
Also, the patients were not in the age range for, nor did they 
have any evidence of, persistent pulmonary hypertension of the 
newborn (17). 
Hemodynamic measurements. Our procedure for cardiac 
catheterization at rest has been described elsewhere (18,19). In 
brief, cardiac output was measured in triplicate by the ther- 
modilution method, and pressures were obtained by a Swan- 
Ganz catheter positioned in the main trunk of the pulmonary 
artery. This catheter was also used for sampling mixed venous 
oxygen tension. In most patients, the brachial artery was also 
cannulated with a Coumand-Potts needle for systemic pres- 
sure recording and arterial blood sampling. Standard formulas 
were used to calculate cardiac index, stroke volume index, 
pulmonary vascular resistance index and systemic resistance. 
We also calculated the pulmonary/systemic vascular resistance 
ratio. 
Vasodilator drug testing and long-term treatment. Most 
patients in this study had at least one short-term trial with a 
vasodilator, and many of them are still under treatmeat W;iih 
these agents. Before testing, we tried to ensure steady state by 
waiting -15 min to obtain baseline hemodynamic values. 
Afterward, the hemodynamic response to l&l% oxygen 
breathing was evaluated in most of the patients. “%e protocol 
for vasodilator testing has remained basically unchanged, but 
the selected vasodilator drug for short-term challenge has 
changed over the years. We have used the following drugs: 
isoproterenol(3 to 5 pgf infused into the pulmonary artery for 
1 min (19): hydralazine (0.33 mg/kg body weight infused into 
the pulmonary artery over 3 min (18); and nifedipine (10 to 
20 mg) administrated sublirlgually (20). On the basis of hemo- 
dynamic i esponse to the short-term vasodilator trial, we clas- 
sified the patients into two groups: responders and nonre- 
sponders. The criteria for a favorable response to vasodilator 
treatment included 1) a significant decrease in mean pulmo- 
nary artery pressure or pulmonary vascular resistance index 
(>20% from baseline); 2) a predominant pulmonary vasodila- 
tory response, as assessed by the decrease in the pulmonary/ 
systemic vascular resistance ratio; and 3) absence of a delete- 
rious effect on pulmonary gas exchange. C.?ly when these three 
criteria were met was the patient considered for vasodilator 
drug treatment. In most patients the response to oral medica- 
tion was evaluated on the ward and reassessed again 1 week 
later. After evaluation of a satisfactory immediate and short- 
term respcmse, the patient was considered for long-term 
vasodilator treatment. 
Other therapeutic measures. Routine anticoagulation was 
not used in our patients until recenrly. Digitalis was only 
occasionally used, and mild diuretic therapy was utilized for 
the treatment of symptomatic right-sided cardiac failure. 
Statistical analysis. 1) We analyzed the clinical and hemo- 
dynamic characteristics of our patients at entry for the whole 
group (n = 18) and separately in those patients with (n = IO) 
and without (n = 8) long-term vasodilator treatment. 2) For 
survival analysis we used the initial diagnostic catheterization 
as an index for determining survival. The Kaplan-Meier 
method was used to estimate overall survival distribution. 
Univariate analysis based on the Cox proportional hazards 
model (22-24) was used to examine the relation between 
survival and selected demographic, medical history, pulmonary 
function, laboratory and hemodynamic variables measured at 
initial catheterization. Results are expressed as rate ratio with 
95% confidence interval Multivariate analysis based on the 
Cox proportional hazards regression analysis was used to 
examine the adjusted independent effect on survival of each 
variable, controlling for possible confounders (23,24). For both 
survival analysis and Cox proportional hazards models we used 
STATA software (22). 3) We compared the clinical, functional, 
hemodynamic and survival results for patients ~16 years old 
with primary pulmonary hypertension with those found in our 
adult patients (I( = 42, mean age 27.9 rt: 8.5 years) with primary 
pulmonary hypertension (13). 
For all other statistical analyses we used paired and un- 
paired 1 tests and linear regression. Results are expressed as 
mean value 2 1 SD. A p value < 0.05 was significant in all 
comparative analysis. 
Results 
Demographic characteristics. All 18 patients are Hispanic 
(mean [ -tSD] a&e 9.9 2 3 years, rang: 4 to 15; 11 girls, 7 boys, 
female/male ratio 1.6:1), and 11 of the 18 were born and raised 
in Mexico City and are current residents there (2,240 m abcye 
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sea level). The other seven patients are from different parts ol 
Mexico. 
Medical and family history. None of the patients had a 
history of appetite suppressant or hormonal drug use. TWO 
patients (11%) had a history of familial pulmonary hyperten- 
sion. One of the two was diagnosed as asymptomatic durifig the 
routine family screening study that all patients underwent. 
Symptoms and physical findings. The frequency of symp- 
toms at diagnosis (initial catheterization) was dyspnea in 940/o, 
syncope or near syncope in 61% and chest pain in 5.5%. 
Eifort-related palpitations and cyanosis were present in 50% 
and 33%, respectively. Leg edema was reported by 11% of the 
patients, and in 2 (11%) of the 18 patients, generalized seizures 
were part of the presenting symptoms. None of the patients 
reported symptoms of Raynaud’s phenomena. Mean time from 
onset of the first symptom to diagnosis of primary pulmonary 
hypertension was 2.06 + 1.93 years (range 0 to 8.2). At 
diagnosis 5.5% of the patients were in New York Heart 
Association functional class I, 33.3% in class II, 38.8% in class 
III and 22.2% in class IV. 
Physical findings in the patients with primary pulmonary 
hypertension wert: those usually found in any patient with 
pulmonary hypertension. An increase in the pulmonary com- 
ponent of the second heart sound (P2) was reported in all 
patients. A soft systolic pulmonary murmur was found in 33% 
of patients, tricuspid regurgitation in 28%, pulmonic insuffi- 
ciency in ll%, cyanosis in 33% and peripheral edema in 
16.5%. 
Laboratory findings. The chest roentgenogram showed the 
typical changes associated with pulmonary hypertension, 
namely prominence of the main pulmonary artery in all 
patients and enlarged hilar vessels in most. Mean diameter of 
the right main pulmonary artery at the parsinterlobaris was 
14.2 + 2.48 mm (normal ~16 mm), and the mean pulmonary 
lobe diameter/maximal transverse diameter of the thorax index 
was 42 t 12.3 (normal ~38) (3,25,26). Mean cardiothoracic 
index of the group was 55 ? 7 and was bO.5 in 66.6% of the 
patients. The electrocardiogram showed sinus rhythm and 
evidence of right ventricu!ar hypertrophy in ail patients. Signs 
of right ventricular strain (i.e., T wave inversion with or 
without ST segment depression in the right precordial leads) 
were Fresent in 78% of patients (3,27). The echocardiogram 
confirmed right ventricular hypertrophy and showed variable 
degrees of right ventricular enlargement (3j. A iune perftision 
scan was obtained in 13 patients and findings were considered 
completely normal in 8 (61.5%). In three patients (23%). the 
lung perfusion scan findings were characterized as abnormal 
and were described as a diffuse bilateral patchy pattern (21). In 
the remaining two patients (15.4%), the distinction between a 
normal and an abnormal patchy pattern was not possible; 
however, in none of the studies there was evidence for lobar or 
single segmental defect. Results of an antinuclear antibody test 
were negative in all patients. Mean hemoglobin level of the 
group was 15.3 c 1.5 g, and total platelet count was rwmal. 
Pulmonary function. Pulmonary function tests could be 
performed in 11 patients (mean age 11 -C 2.7 years). Mean 
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values of selected variables are presented in Table 1. Mild 
pulmonary restriction as assessed by the decrease in both vital 
capacity and total lung capacity was present in 33% of patients. 
‘There was no evidence for airway obstruction. Mild to mod- 
erate hypoxemia was present in 4(i% of patients, and hypocap- 
nia with normal pH was present in all. Normal values for 
Mexico City are arterial oxygen isnsion 67.5 j: 2.5 mm Hg and 
arterial carbon dioxide tension 35 t- 2.5 mm Hg (28). The 
arterial oxygen tension correlated significantly with the mixed 
venous oxygen tension (r = 0.58, p < 0.05). Dead space as well 
as total shunt were only slightly increased in most of the 
patients. Diffusing capacity for carbon monoxide was not 
measured. 
Hemodynamic findings. In Table 1 selected hemodynamic 
variables in children with primary pulmonary hypertension at 
the time of initial diagnostic catheterization are summarized 
and compared with those in the adult group. Children with 
primary pulmonary hypertension had severe pulmonary arte- 
rial hypertension, with a threefold increase in mean pulmonary 
pressure (66 -+ 15 mm Hg, range 36 to 89), a mild elevation in 
right atria1 pressure (5.4 2 2 mm Hg, range 1 to 9.5) and right 
ventricular end-diastolic pressure (7.6 L 4 mm Hg, range 1 to 
15.6), a normal pulmonary capillary wedge pressure and a 
mildly reduced to normal cardiac index (4.1 2 1.5 liters/min 
per m2, range 1.9 to 8.37). Calculated pulmonary vascular 
resistance index was 18.4 + 7 U/m’. Mean pulmonary/systemic 
vascular resistance ratio for the whole group was 0.91 f 0.21. 
Patients with more severe symptoms (functional class III or 
IV) had a higher right ventricular end-diastolic pressure than 
did their less symptomatic counterparts (functional class I or 
II) (9.1 ? 3.9 vs. 5.45 t 3.8 mm Hg, respectively, p < 0.05). 
There was no correlation between the hemodynamic values 
and duration of symptoms before diagnosis. As noted in Table 
1, except for mean pulmonary artery pressure asd pulmonaryl 
systemic vascular resistance ratio, hemodynamic variables in 
children with primary pulmonary hypertension were signifi- 
cantly different from those in the adult group, and the children 
had significantly lower right atria1 and right ventricular end- 
diastolic pressures and a ‘;gbzr cardiac index than their 
counterparts in the adult group. Pulmonary vascular resistance 
index was not modified by oxygen breathing in the group as a 
whole (22.6 -C 2.76 U/m* before vs. 22.87 f 2.53 U/m2 after, 
p = NS). 
Immediate hemodynamic response to vasodilator drags. 
The hemodynamic response to the short-term administration 
of vasodilators could be assessed in 17 of the patients (Table 
2). Seven of the 17 patients did not respond to vasodilator 
therapy (nonresponders). In these patients, neither pulmonary 
artery pressure nor pulmonary vascular resistance index were 
decreased by administration of the drug. Nonresponder chil- 
dren had a significantly higher baseline pulmonary artery 
pressure than did their counterpart responder children (74.3 2 
15 vs. 57.9 + 13.3 mm Hg, respectively). There were no 
di$erences in cardiac index and right atria1 pressure. Of the 
responders (n = lo), seven patients (Patients 4, 18,21,42,45, 
56 and 57) had an immediate and significant decrease (>20%) 
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Table 1. Pulmonary Function Variables and Hemodynamic Findings at Study Entry 
_11_1 
Chtldren Adults p Value - 
Pulmonary function n-11 n = 42 
TLC (% of predicted) 08 2 23 022 15 NS 
FVC (% of predicted) 89.9 t 30.7 63.4 f 23.3 NS 
FEV, (% of predicted) 103.5 + 24.1 85 -c 18 < 0.005 
FEFz_,, (% of predicted) 99.8 It 30.3 89 t 25 NS 
Paoa (mm Hg)* 65.4 5 5.0 62.3 2 8.0 NS 
Pace, (mm Hg)t 28.6 2 3.6 27.1 IC_ 3.2 NS 
Arterial pH$ 7.42 + 0.04 ‘1.44 2 0.03 NS 
Vd/Vt (%) 0.42 rt 0.08 0 42 t 0.09 NS 
Qs/Qt (%) 7.7 + 2.3 8.9 ? 3.82 NS 
Hemodynamic variables “= 18 n = 42 
HR (beats/mitt) 98 t 16 81 2 14 < 0.001 
RAP (mm W 5.4 ” 2 1.7 r 4.9 0.01 
RVEDP (mm Hg) 7.6 -t 4.0 11.2 + 6.0 0.03 
PAP 
Systolic (mm Hg) 94 i 20 97 t 28 NS 
Diastolic (mm Hg) 46x11 47 2 13 NS 
Mean (mm Hg) 66~ 15 65 2 18 NS 
PCWP (mm Hg) 5.7 2 4.4 9CS < 0.05 
SAP (mm Hg) 71 i 10 83 % 17 < 0.005 
Cl (litersimin m*) per 4.1 ? 1.52 2.75 2 0.97 < 0.005 
Wo, (mm Hg) 34 rt 4 32 2 I NS 
PVRI (U/m*) 18.4 f 7.08 25.9 C 12 <: 0.01 
RpiRs 0.9 2 0.21 0.79 i 0.29 NS 
*Normal values for Mexico‘City 67.5 2 2.5 mm Hg (28). lNormal values for Mexico City 32.2 2 2.5 mm Hg (28). 
*Normal values for Mexico City 7.33 to 7.43 (28). Data presented are mean value ?SD or number of patients. Cl = 
cardiac index; FEF,_,s = maximal midexpiratory ffow; FEV, = forced expiratory volume in 1 s: FVC = forced vital 
capacity; HR = heart sate; Pace, = arterial carbon dioxide pressure; Pao, = arterial oxygen pressure; PAP (SAP) = 
pulmonary artery (systemic arterial) pressure; PCWP = puhnonary capillary wedge pressure; P?o, = mixed venous 
oxygen pressure; PVRI = pulmonary vascular resistance index; QdQt = intrapulmonary shunt; RAP = right atria1 
pressure; Rp/Rs = pulmonary/systemic resistance ratio: RVEDP = right ventricular end-diastolic pressure: TLC = total 
lung capacity; VdNt = physiologic dead space 
in both pulmonary artery pressure and pulmonary vascular 
resistance index after administration of the drug. The propor- 
tion of patients with this response was higher in children (7 
[58%] of 17) than in adults (8 [25%] of 31) with primaty 
pulmonary hypertension. In the remaining three patients (Pa- 
tients 15, 24 and 46) the response was characterized by a 
significant decrease in pulmonary vascular resistance index 
only (i.e., increase in cardiac index, but no change in pulmo- 
nary artery pressure). We found no significant correlation 
between age and the immediate response to the vasodilator, as 
assessed by change in pulmonary artery pressure (r = -0.25, 
p = NS) or change in pulmonary vascular resistance index (r = 
-0.26, p = NS), or both, but the decrease in both pulmonary 
artery pressure and pulmonary vascular resistance index in 
response to the vasodilator was more frequent (40%) in 
children <IO years old than in those >lO years old (28.5%). 
Treatment with vasodilator drugs. On the basis of the 
results of the short-term vasodilator trial, patients with a 
beneficial hemodynamic response (n = 10) received long-term 
vasodilator treatment (nifedipine in 9, hydralazine in 1). Eight 
of the 18 patients had no vasodilator treatment. This group 
includes the seven nonresponder patients and one patient who 
did not undergo a short-term vasodilator trial. Among the 
patients with treatment, four died, and one was lost to follow- 
up. At present, four (80%) of the five remaining treated 
patients receive nifedipine (mean daily dose 40 mg), and one 
patient still receives hydralazine (after 13 years). The long- 
term hemodynamic status of patients with vasodilator treat- 
ment was assessed by repeated catheterization, and these 
results are also shown in Table 2. Only patients with a 
significant decrease in pulmonary artery pressure and puimo- 
nary vascular resistance index in the short-term trial (Patients 
4, 18, 21 and 56) did these variables remain lower than 
originally calculated (at baseline). 
Swvival. By September 1992, 5 of the 18 patients with 
primary pulmonary hypertension had died, and none of these 
5 survived >5 years (mean survival time 29.2 months). Bight 
heart failure either alone or combined with other events 
(discontinuation of treatment [n = 11, cardiac catheterization 
[n = 21) was the cause of death in all patients. Postmortem 
findinks were available in two of these patients. Both had 
marked enlargement and hypertrophy of the right side of the 
heart, and there was great dilation of the pulmonary artery and 
its branches in the lungs, together with lipid deposits. Micro- 
scopic examination of &!v &nail pulmonary arterioles showed 
medial hypertrophy and weIl marked intimal proliferation that 
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Table 2. Baseline Values and Immediate and Late Effects of Vasodilator Therapy on Mean Hemodynamic Variables in F’aticnls With Primary 
Pulmonary Hypertension 
--. --_1_1 
Baseline Values Immediate Response Law Effects 
-- - 
Pt No./ Age PAP a PVRI PAP CI PVRI PAP Cl PVRl Time 
Gender (yr) (mm Hg) (liters/min per rn’) (Vim’) (mm Hg) (iitcr~/min per m’) (U,‘m’) (mm Hg) (literdmin per mL) (U/m’) (Yd 
4/M 15 48 4.4 11 ;I 4.0 4 2s 5.2 3.8 10.25 
15/M 15 36 2.8 1; 34 4.5 7.6 54 3.2 17 0." 
13/T: 9 51 2.2 26 31 2.2 14 54 3,s IS.3 0.75 
21/F 10 62 5.3 12 40 6.4 6 53 4.5 11.8 25 
46/M 15 80 3.2 25 81 4.7 17 71 2.7 26 0.08 
56ff 8 7: 2.8 25 35 4.0 9 45 3.1 14.5 2.3 
24F 10 42 4.7 9 37 5.9 6 
42/F 8 57.5 3.2 18 46 4.9 9 
45w 7 67 5.6 l? 53 6.0 Y 
57,F I1 57.5 2.5 23 29 3.5 8 
R-LT 
Mean 5’; 3.4 18.6 39* 4.3' 9.6* 50 3.7 15 2.15 
,SD 14.5 1.116 6.1 19 1.2 4.5 13.5 0.X 6.3 3.4 
K-i 
Mean 58 3.35 17.4 40' 4.5" Y' 
ZSD 13 1.16 6.S 17 1.15 3.8 
NR 
Mean 74 4.67 18 82 4.84 19 
rSD 15t 1.8 7.5 15 1.8 7 
“p < 0.05 different from baselme values by paired I test. tp < 0.05 different from responders by unpaired r test. F = female; M = male; NR = nonresponders; 
Pt = patient; R-I = responders, immediate response; R-LT = responders, long-term response; other abbreviations as in Table 1. 
significantly narrowed the vessel lumen. No plexiform lesions 
were identified, and no thromboemboli were found in the large 
or small pulmonary arteries on careful examination. The main 
pulmonary artery showed fewer, shorter and more irregular 
elastic fibers than the aorta, indicating that pulmonary hyper- 
tension was acquired after birth. 
Summary statistics on survival and length of follow-up for 
the 18 evaluable patients are shown in Figure 1. Two (11%) of 
the 18 patients were followed up <l year, 16 (88.8%) for at 
Figure 1. Kaplan-Meier survival estimates in 18 children (solid sym- 
bols) and 42 adults (open symbols) with primary pulmonary hyperten- 
sion from baseline catheterization. Median survival estimates for 
children and adults are 4.12 years (95% confidence interval [CI] 0.75 to 
8.66) and 3.12 years (95% CI 0.5 to 13.25), respectively (chi-square 
log-rank 0.81. p = NS). 
% SURVIWNG 
. _ --- ~~~_..._.. _..--~-. 
0 1 6 8 91113151823242748425353BS72 
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least 1 year, 12 (66.6%) for at leaat 2 jears, 11 (61.1%) for at 
least 3 years, 11 (61.1%) for at least 4 years and 7 (38.8%) for 
at least 5 years. Four patients were lost to follow-up at different 
times. Median survival for the children with primary puhno- 
nary hypertension was 4.12 years (range 4 months to 14.6 years, 
95% confidence interval [Cl] 0.75 to 8.66), not statistically 
different from the 3.12-year median survival for adults with 
primary pulmonary hypertension (range 1 month to 15.2 years, 
95% Cl 0.5 to 13.25, chi-square log-rank 0.81, p = NS) (Fig. 1). 
As previously mentioned, 10 patients (55.5%) had Iong- 
term vasodilator therapy after discharge. We compared sur- 
vival times for patients receiving vasodilator drug therapy at 
discharge with those of patients not receiving such therapy. 
Median survival time was 4.41 years (range 0.33 to 8.66, 95% 
CI 0.75 to 7.33) for those without vasodilator treatment at 
discharge and 4.04 years (range 1.33 to 14.66, 95% CI 1.33 to 
8.41) for those with vasodilator treatment (chi+quare log-rank 
0.39, p = NS). 
Seven (38.8%) of the 18 patients survived >5 years (mean 
survival 94.8 2 36.9 months), and 5 (27.7%) died (mean 
survival 29.2 2 16.4 months). There were significant differ- 
ences (p < 0.05), respectively, in baseIine right ventricular 
end-diastolic pressure (6.25 t 3.52 vs. 11.8 2 3.03 mm Hgj, 
cardiac index (5.40 -t 1.3 vs. 3.04 z 0.55 Iiters/min per m2j, 
mixed venous oxygen tension (35.2 t- 2.0 vs. 30.5 2 
4.5 mm Hgj, pulmonary vascular resistance index (12.5 r 4.3 
vs. 21 -C 4.4 U/m’) and stroke volume index (52.V z 7.58 vs. 
34.8 -C 10.6 ml/beat per m’) between the two groups. 
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Table 3. Univariate Analysis Relating Survival Time With Selected 
Baseline Variables 
Demographic and historical data 
Age 
Female gender 
NYHA functional class III or IV 
Systemic venous congestion 
Acute response to vasodilator 
Hazard Ratio 
(95% CI) 
1.09 (0.78-1.53) 
0.30 (0.44-2.09) 
2.30 (0X-24.4) 
3.84 (OS26.8) 
0.34 (0.03-3.75) 
P 
Value 
ti.50 
0.21 
0.46 
0.16 
0.36 
Vasodilator treatment 
Pulmonary function tests 
NC 
FEV, 
0.32(0.03-3.47) 0.33 
0 9 16 0.94(O.W22.5) 0.9' 24 48 49 
1.46: - 16 1.00 MONTHS 
Hemodynamic variable 
HR (>87 beatsimin) 0.44 (0.06-3.10) 0.39 
RAP (b7.4 mm Hg) S.41 (0.99-71.0) 0.05 
RVEDP (b10.4 mm Hg) 5 10 (0.73-35.3) 0.09 
PAP (265.8 mm Hg) 1.28 (0.18-8.84) 0.78 
SAP (40 mm Hg) 0.88 (0.10-7.67) 0.90 
Cl (< 3 litersimin Per m’) 3.35 (0.47-23.9) 0.21 
PVRI (>24.3 U/m’) 2.17(0.30-15.6) 0.41 
SVRI (>29.7 IJim”) 2.30(0.19-27.7) 0.48 
Rp/Rs (sO.89) 1.65 (0.23-11.6) 0.59 
SVI (K37.5 ml/beat per m*) 8.83 (0.79-97.7) 0.07 
Gas exchange 
Paoz (~56 mm Hg) 1.35 (0.11-16.5) 0.79 
PVo, (~31.4 mm Hg) 7.62 (0.84-68.5) 0.06 
CI = confidence interval; NYHA = New York Heart Association; SVRI = 
systemic vascular resistance index; other abbreviations as in Table 1. 
Figure 2. Kaplan-Me& survival estimates for patients with primary 
pulmonary hypertension with right atria1 pressure >7.5 mm Hg (open 
s+ymbols) and ~7.5 mm Hg (solid symbols). Median survival estimates 
are 1.33 years (95% confidence interval [CI] 0.33 to 4.0) and 4.83 years 
(95% CI 0.75 tc 14.66), respectively j&i-square log-rank 6.22, p = 
0.01). 
cant predictor of mortality. For illustration, the Kaplan-Meier 
survival curve for patients with primary pulmonary hyperten- 
sion according to right atria1 pressure (~7.5 and >7.5 mm Hg) 
is shown in Figure 2. 
After completion of univariate analysis, any variable that 
was p < 0.25 (Table 3) was considered a candidate for the 
multivariate model because the use of a more traditional p 
value (e.g., p = 0.05) often fails to identify variables known to 
be important (23,24). When each of these variables was 
adjusted for agk and gender, only decreasc*d stroke volume 
index (rate ratio 32.9, 95% CI 1.02 to 1,058, p < 0.04) and 
increased right atria1 pressure (rate ratio 10.2, 95% CI 0.96 to 
108.2, p < 0.053) were associated with an increased risk of 
death. Compared with the variable of vasodiiator treatment, 
these two hemodynamic variables were still associated with 
mortality; however, the 95% confidence intervals go up to 1.0 
(p = NS) (Table 4). 
Discussion 
Primary pulmonary hypertension is widely recognized as a 
disease of young people (3,29,30), with certain features of the 
disease differing before and after pubertv (31). However, very 
little information exists regarding clinical characterization, 
natural history, response to treatment and survival in the 
pediatric population (32-36). This relative lack of knowledge is 
partly due to the fact that primary pulmonary hypertension is 
itself a relatively uncommon disease and has its highest 
frequency beyond the pediatric age (3,4,7,8,13,29,35). 
The 18 patients discussed here represent a dynamic cohort 
of children with primary pulmonary hypertension in whom the 
diagnostic and therapeutic criteria, as well as the follow-up 
approach, were applied in all patients by the same group of 
investigators. In contrast to other clinical studies of primary 
pulmonary hypertension in children (33,34), the age range in 
our study was limited to the pediatric and puberty periods only. 
Factors associated with survival in univariate and multiva- 
riate analysis. Univariate analysis of the relation between 
mortality and variables measured at entry (initial catheteriza- 
tion) are shown in Table 3. Mortality was not associated with 
age at diagnosis, family history of primary pulmonary hyper- 
tension, Raynaud’s phenomenon or syncope or with the ap- 
parent duration of symptoms before diagnosis. Likewise, pul- 
monary function tests were not predictive of survival. However, 
functional class III or IV (rate ratio 2.3) and clinical evidence 
of systemic venous congestion (rate ratio 3.84) were associated 
with an increased risk of death, whereas female gender (rate 
ratio 0.30), favorable hemodynamic response to vasodilators 
(rate ratio 0.34) and an elevated baseline heart rate (rate ratio 
0.44) had a protective effect against such a risk. 
Of the hemodynamic variables at diagnosis, mean systemic 
and mean pulmonary artery pressures and the pulmonary/ 
systemic vascular resistance ratio did not affect survival. How- 
ever, increased right atria1 pressure (rate ratio 8.41), increased 
right ventricular end-diastolic pressure (rate ratio 5.10), de- 
creased cardiac index (rate ratio = 3.35) and decreased mixed 
venous oxygen tension (rate ratio 7.62) all were associated with 
an increased risk of death. Likewise, variables derived from 
these measured hemodynamic variables, such as increased 
pulmonary vascular resistance index and decreased stroke 
volume index, were also associated with mortality. Even 
though all of these variables were associated with a poor 
survival, right atria1 pressure was the only statistically signifi- 
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Table 4. Adjusted Hazard Ratios for Selected Variables for Survival Obtained From Cox Proporilonal Hazards Regression Analysis 
Regression I * Regression 2t Regression 34 
Hazard Ratio (9% Ci) p Value Eaud Ratio (95% Cl) p Value Hazard Ratio (9% CI) p Value 
Age 1.02 (0.03-2.37) 0.21 0.95 (0,004-l .32) 0.07 
Gender 0.26 (0.77-1.36) 0.84 0.07 (0.67-! .34) 0.77 
RAP 10.2 (0.96-lua) 0.05 3.65 (0.34-38.7) 0.25 
WI 32.9 (1.02-1058) 0.04 6.70 (0.52-85.4) 0.13 
Vasodilator treatment 0.65 (0.04-9.43) 0.73 
*Independent variables include age, gender and right atria1 pressure (RAP); log likelihood -9.7083, chi-square 5.92, p < 0.11. tIndependent variables include age, 
gender and stroke volume index (SVI); log likelihood -7.7448, chi-square 9.84, p < 0.02. gIndependent variables include right atria1 pressure, stroke volume index and 
vasodilator treatment; log likelihood = -8.9636, chi-square = 7.14, p < 0.06. CI = confidence interval. 
Data from patients with persistent pulmonary hypertension of 
the newborn (17) and those from young adults with primary 
pulmonary hgertension were excluded. The present study was 
performed at an altitude of 2,240 m and included both patients 
who were born and raised at this altitude as well as those from 
lower altitudes or even sea level. Accordingly, the separate 
effect of relative acute and chronic altitude hypoxia on pulmo- 
nary hemodynamic variables has to be considered. The lack of 
hemodynamic response to oxygen breathing that we observed 
tends to support the idea that relative alveolar hypoxia at this 
altitude does not make our patients clinically different from 
those who have the disease elsewhere (13,18). Moreover, in the 
National Institutes of Health Registry on primary pulmonary 
hypertension (6), neither survival rate nor clinical variables nor 
hemodynamic variables in patients with primary pulmonary 
hypertension were affected by the altitude of the reporting 
center. For these reasons and for its prospective nature, we 
believe that the present study adds pertinent information to 
the clinical characterization and natural history of children 
affected with primary pulmonary hypertension. 
Clinical characterization. As in previous studies (2,32,35), 
we found that the gender distribution in primary pulmonary 
hypertension is more uniform in children (female/male ratio 
1.6:1) than in adults (female/male ratio 4.25:1). This female 
preponderance after puberty has led to speculation that hor- 
monal influences contribute to the pathogenesis of the disease 
(30-32). 
With regard to the clinical presentation of childhood pri- 
mary pulmonary hypertension there are similarities as well as 
some differences compared with that in adults, and our results 
are in general agreement with previous reports (35). As in 
adults with primary pulmonary hypertension (4,35), dyspnea is 
the most common symptom at diagnosis in children with the 
disease, and syncope, with or without generalized seizures, is a 
more frequent presenting symptom in young children than in 
adults with the disease. By contrast, angina is an uncommon 
symptom in children, which may be related to the difficulty of 
assessing typical angina correctly in this age group. Likewise, 
edema as a reflection of right ventricular failure is somewhat 
less frequent in children (10%) than in adults with primary 
pulmonary hypertension (20%). However, unlike other inves- 
tigators (35), we found that edema is likely to occur even in 
children ~10 years old in the presence of severe right ventric- 
ular dysfunction. In our study, the two children with edema at 
diagnosis had a right ventricu!ar end-diastolic pressure of 14.5 
and 15.5 mm Hg respectively. Finally, Raynaud’s phenomenon 
does not occur in childhood primary pulmonary hypertension. 
With regard to hemodynamic function, despite an earlier 
age, these children already had severe pulmonary hypertension 
with pulmonary artery pressure not significantly diiferent from 
that in the adult group (Table 1). This finding is ili agreement 
with the current concept that once the patient with primary 
pulmonary hypertension becomes symptomatic enough to be 
diagnosed, the pulmonary artery pressure is already high and 
remains elevated without further elrvation with increasing age 
(3,4). Baseline cardiac index was higher in the children, 
probably due to higher oxygen consumption in this age group. 
As a result of a higher cardiac index, the calculated pulmonary 
vascular resistance index was significantly lower in the children, 
and right ventricular function as assessed by right atrial pressure 
and cardiac index appears to be better in children than in 
adults with primary pulmonary hypertension (Table 1). Both of 
these findings suggest an earlier stage of the disease in the 
study children (3,30,35). It is also likely that patients with 
primary pulmonary hypertension who present at a younger age 
are better able to compensate for right ventricular hypertrophy 
than their adult counterparts. 
Response to vasodiJator &ugs. As in adults (3,18,34,37), 
not all children with primary p Jlmonary hypertension respond 
to vasodilator therapy. However, the present study confirms 
and extends previous observations (34,35) that children with 
primary pul,~~onary hypertension generally respond better to 
vasodilator therapy than their adult counterparts. In our 
experience, when the significant decrease in both mean pul- 
monary artery pressure and pulmonary vascular resistance 
index is considered a positive response, the proportion of 
children who respond is higher (41Y0) than that for adults 
(25%). Previous histopathologic studies (30,32) in children and 
adults with primary pulmonary hypertension support this ob- 
servation because greater pulmonary vascular medial hyper- 
trophy and less intimal fibrosis and fewer plexiform lesions 
were found in children than ia adult: in whom irreversible 
changes associated with intimaf fibrosis have developed, sug- 
gesting a more vasoreactive pulmonary vascular bed in chil- 
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dren. With regard to the vasodilator response itself, there is no 
accepted definition of what constitutes a favorable response 
(37). Wowever we believe, as do others (3,37-40) that decreas- 
ing pulmonary artery pressure, not only pulmonary vascular 
resistance index, seems to be the appropriate physiologic and 
therapeutic response. As shown in Table 2, only patients with 
this response sustain a long-term hemodynamic benefit. 
Our finding that younger patients with primary pulmonary 
hypertension have a better hemodynamic response to vasodi- 
later therapy agrees with that of Barst (34), who found that 
vasodilator therapy produced a greater decrease in pulmonary 
artery pressure in younger than older patients. However, we 
did not observe any significant correlation between age and 
hemodynamic response to vasodilator treatment in our group 
of children with primaty pulmonary hypertens;on, which may 
be a result of our limiting the study to the pediatric and 
puberty period (4 to 15 years of age), whereas Barst (34) 
included both infants and young adults (9 months to 23 years 
old). In fact, when correlations from that study were repeated 
by using the data for Patients 3 to 7 (the same age range as our 
patients), most correlations were not statistically sign&ant. 
Natural history. A major objective of the present study was 
to determine whether sutvival in children with primary pulmo- 
nary hypertension is better than that in adults with the disease 
if the diagnosis is made earlier in life. Our results show that 
childhood primary pulmonary hypertension is a disease with a 
poor prognosis and a survival expectancy not statistically 
different from that in the adult disease (Fig. 1). To some extent 
this finding is unexpected because of 1) the younger age, 2) the 
relatively better baseline hemodynamic profile, and 3) the 
better hemodynamic response to vasodilator therapy observed 
in children in the present study. We do not have a clear 
explanation for the finding of similar survival expectancy in 
children and adults with primary pulmcaary hypertension, and, 
except for the study of Barst et al. (33), there is very little 
published information in this regard. In a group of patients 
with primary pulmonary hypertension (9 months to 23 years 
old), Barst et al. (33) found that age at diagnosis and imme- 
diate prostaglandin I, vasodilator response were significant 
predictors of survival. They concluded that children with 
primary pulmonary hypertension diagnosed early in life who 
receic: long-term vasodilator therapy, on the basis of a positive 
response to short-term prostaglandin I, testing, have an in- 
creased life expectancy. As shown in the present study and as 
discussed later, neither age at diagnosis nor response to 
vasodilator therapy was associated with survival according to 
univariate and multivariate analysis. However, an important 
difference between the two studies is the age range of the 
patients studied. In the study of Barst et al. (33), both infants 
and young adults were included, making the significance of 
their results difficult to interpret. Another difference is that we 
did not use prostacyclin as the testing agent. 
Although discontinuation of treatment (one patient) and 
repeated (follow-up) right heart catheterization (two patients) 
might be implicated, right heart failure either alone or com- 
bined with these events was the leading cause of death in our 
o- 
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Figure 3. Real (salid symbols) versus predicted (open symbols) sur- 
vival in children with prirrar)i puim2nary hypertension. Predicted 
survival cume was constructed with the mean values of the survival 
estimates predicted by the equation proposed by the National Insti- 
tutes of Health study on primary pulmonary hypertension (6,13). 
patients. Accordingly, our pediatric patients with primary 
pulmonary hypertension appear to have evolved, as have most 
of their counterparts in the adult group, to right heart failure 
and death. This observation is supported by previous investi- 
gators (32), who also found that early right ventricular failure 
and death may occur in children with primary pulmonary 
hypertension even in the absence of advanced vascular lesions. 
Factors associated with survival. In contrast to previous 
experience (35) but similar to other multiple studies on 
primary pulmonary hypertension in the general population 
(3,6,13-16) survival in childhood primary pulmonary hyper- 
tension in our study also appears to be related to the hemo- 
dynamic profile of the patients at diagnosis; once right ventric- 
ular failure develops, the prognosis is extremely poor. In our 
study patients with primary pulmonary hypertension who died 
had a worse and significantly different hemodynamic profile at 
diagnosis than those who survived >5 years. Furthermore, 
although not statistically significant by multivariate analysis 
(perhaps because of sample size), both elevated right atrial 
pressure and decreased stroke volume index are the variables 
most strongly associat? ” with increased risk of death in this 
group of children with primary pulmonary hypertension (Fig. 
2). Taken together these abnormalities are a reflection of right 
ventricular failure. It then appears that the prognosis of 
children with primary pulmonary hypertension depends on the 
functional status of the right ventricle, as is the case for the 
general population with thi, disease (3,6,13-16): and could 
thus be predictable. In support of this statement is the close 
correlation between actual sur ival and survival as predicted by 
the prognostic equation recently proposed by the National 
Institutes of Health Registry on prima? pulmonary hyperten- 
sion (6,13) (Fig. 3). As mentioned earlier, other variables 
reported to be important determinants of survival in children 
with primary pulmonary hypertension, such as age at diagnosis 
and beneficial hemodynamic :esponse to vasodilator treatment 
(33$5), were not associated with survival in our study, which 
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might be explained by the more &ictly limited pediatric age 
included in our study. 
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